Lumacaftor
Based on 20 publication(s) in Google Scholar
Lumacaftor (VX-809; VRT 826809) is a CFTR modulator that corrects the folding and trafficking of CFTR protein.
For research use only. We do not sell to patients.
- Purity: 99.85%
- CAS No.: 936727-05-8
- Formula: C24H18F2N2O5
- Molecular Weight:452.41
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocol
- Purity & Documentation
- References
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
Membrane Transporter/Ion Channel Compound Library
HY-L011
-
FDA-Approved Drug Library
HY-L022
-
Autophagy Compound Library
HY-L029
-
Drug Repurposing Compound Library
HY-L035
-
Orally Active Compound Library
HY-L061
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Rare Diseases Drug Library
HY-L102
-
EMA-Approved Drug Library
HY-L116
-
Human Metabolite Library
HY-L123
-
Off-patent Drug Library
HY-L141
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Cell Death Library
HY-L162
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
Publications Citing Use of MedChemExpress (MCE) Lumacaftor
More- Cell. 2022 Jan 6;185(1):158-168.e11. [Abstract]
- J Clin Invest. 2024 Jul 2:e176328. [Abstract]
- Acta Pharmacol Sin. 2025 Apr;46(4):1045-1057. [Abstract]
- J Med Chem. 2025 Feb 27;68(4):4596-4618. [Abstract]
- Cells. 2025 Oct 15;14(20):1601. [Abstract]
- Cells. 2022 Jan 18;11(3):319. [Abstract]
- Stem Cell Reports. 2020 Nov 10;15(5):1127-1139. [Abstract]
- Int J Mol Sci. 2022 Aug 25;23(17):9612. [Abstract]
- Sci Rep. 2025 Apr 21;15(1):13767. [Abstract]
- J Biol Chem. 2024 Nov;300(11):107873. [Abstract]
- Sci Rep. 2020 Oct 2;10(1):16383. [Abstract]
- Sci Rep. 2015 Oct 30;5:15946. [Abstract]
- PNAS Nexus. 2025 Jul 4;4(7):pgaf211. [Abstract]
- J Physiol Sci. 2019 Jan;69(1):103-112. [Abstract]
- Mol Biol Cell. 2022 Nov 1;33(13):ar120. [Abstract]
- Virology. 2023 Aug:585:205-214. [Abstract]
- Patent. US20240252655A1.
- University of Kentucky. 2022 Aug.
- bioRxiv. April 30, 2021.
- Patent. US20150328217A1.
Customer Validation & Images
-
Flow Cytometry
-
WB
-
Bio/Physico-chemical Assay
-
Bio/Physico-chemical Assay
-
Bio/Physico-chemical Assay
Biological Activity
EC50: 0.1 μM (CFTR)[1]
In fischer rat thyroid (FRT) cells, Lumacaftor improves F508del-CFTR maturation by 7.1±0.3 fold (n=3) compared with vehicle-treated cells (EC50, 0.1±0.1 μM; n=3) and enhances F508del-CFTR-mediated chloride transport by approximately fivefold (EC50, 0.5±0.1 μM; n=3). At Lumacaftor concentrations greater than 10 μM, the response is reduced, resulting in a bell-shaped dose-response relationship with an IC50 of approximately 100 μM. Lumacaftor is orally bioavailable in rats and achieved in vivo plasma levels significantly above concentrations required for in vitro efficacy[1]. Lumacaftor produces a concentration-dependent increase in the HRP luminescence signal after incubation with cells at 37°C or 27°C in both cell lines, with a similar EC50 value of approximately 0.3 μM. In F508-HRP CFBE41o- cells at 37°C, Lumacaftor increases the signal maximally to approximately 250 luminescence arbitrary units (a.u.) over the DMSO control baseline of approximately 60 a.u., representing an approximately 4-fold signal increase. Similarly, with the R1070W-HRP CFBE41o- cells, Lumacaftor increases the signal maximally to approximately 220 a.u. over the DMSO control baseline of approximately 85 a.u., representing an approximately 2.5-fold signal increase. Therefore, both cell lines produced robust signals with a good dynamic range for high-throughput screening[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 936727-05-8
-
Appearance Solid
-
Molecular Weight 452.41
-
Formula C24H18F2N2O5
-
Color Off-white to light yellow
-
SMILES
FC1(F)OC(C=C(C=C2)C3(CC3)C(NC4=NC(C5=CC=CC(C(O)=O)=C5)=C(C=C4)C)=O)=C2O1
-
Synonyms
VX-809; VRT 826809
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 1 year -20°C 6 months
Publications (20)
-
Journal Impact Factor
-
Most Recent
-
Cell
2022 Jan 6;185(1):158-168.e11. PMID: 34995514
Lumacaftor purchased from MedChemExpress. Usage Cited in: Cell. 2022 Jan 6;185(1):158-168.e11. [Abstract]
The addition of Lumacaftor (1 µM) increased the presence of ΔF508-CFTR at the plasma membrane in HEK293F cells.
Lumacaftor purchased from MedChemExpress. Usage Cited in: Cell. 2022 Jan 6;185(1):158-168.e11. [Abstract]
Saturation binding and nonlinear regression analysis of [3H]Lumacaftor (0-200 nM) binding to wtCFTR in the absence of phosphorylation and ATP (Kd = 8.3 ± 2.2 nM). Specific binding of [3H]Lumacaftor to wtCFTR increased as a function of its concentration.
Lumacaftor purchased from MedChemExpress. Usage Cited in: Cell. 2022 Jan 6;185(1):158-168.e11. [Abstract]
Competition binding assay. The binding of [H3]Lumacaftor (10 nM) was plotted as a function of the competitor's concentration. The Ki of unlabeled Lumacaftor (10-104 nM) was determined to be 7.7 ± 2.0 nM.
-
J Clin Invest
Potentiation of BKCa channels by cystic fibrosis transmembrane conductance regulator (CFTR) correctors VX-445 and VX-121. [Abstract]2024 Jul 2:e176328. PMID: 38954478 -
Acta Pharmacol Sin
Ivacaftor, a CFTR potentiator, synergizes with osimertinib against acquired resistance to osimertinib in NSCLC by regulating CFTR-PTEN-AKT axis. [Abstract]2025 Apr;46(4):1045-1057. PMID: 39627385 -
J Med Chem
Target Identification with Live-Cell Photoaffinity Labeling and Mechanism of Action Elucidation of ARN23765, a Highly Potent CFTR Corrector. [Abstract]2025 Feb 27;68(4):4596-4618. PMID: 39928576 -
Cells
Mitochondrial Fragmentation Induced by the CFTR Modulators Lumacaftor and Ivacaftor in Immortalized Cystic Fibrosis Cell Lines. [Abstract]2025 Oct 15;14(20):1601. PMID: 41148816
Lumacaftor purchased from MedChemExpress. Usage Cited in: Cells. 2025 Oct 15;14(20):1601. [Abstract]
The corrector Lumacaftor (VX-809) (10 μM; 48 h) significantly increased the cROS levels in IB3-1 cells.
-
Cells
Assessment of FDA-Approved Drugs as a Therapeutic Approach for Niemann-Pick Disease Type C1 Using Patient-Specific iPSC-Based Model Systems. [Abstract]2022 Jan 18;11(3):319. PMID: 35159129 -
Stem Cell Reports
Isogenic Sets of hiPSC-CMs Harboring Distinct KCNH2 Mutations Differ Functionally and in Susceptibility to Drug-Induced Arrhythmias. [Abstract]2020 Nov 10;15(5):1127-1139. PMID: 33176122
Lumacaftor purchased from MedChemExpress. Usage Cited in: Stem Cell Reports. 2020 Nov 10;15(5):1127-1139. [Abstract]
Lumacaftor (5 μM; 8 d) significantly shortened the FPD in the KCNH2 variant lines.
-
Int J Mol Sci
2022 Aug 25;23(17):9612. PMID: 36077010 -
Sci Rep
CFTR acts as a potential therapeutic target for attention deficit-hyperactivity disorder. [Abstract]2025 Apr 21;15(1):13767. PMID: 40258939 -
J Biol Chem
A nonnatural peptide targeting the A-kinase anchoring function of PI3Kγ for therapeutic cAMP modulation in pulmonary cells. [Abstract]2024 Nov;300(11):107873. PMID: 39393573 -
Sci Rep
Characterization of five novel vasopressin V2 receptor mutants causing nephrogenic diabetes insipidus reveals a role of tolvaptan for M272R-V2R mutation. [Abstract]2020 Oct 2;10(1):16383. PMID: 33009446 -
Sci Rep
CFTR-regulated MAPK/NF-κB signaling in pulmonary inflammation in thermal inhalation injury. [Abstract]2015 Oct 30;5:15946. PMID: 26515683
Lumacaftor purchased from MedChemExpress. Usage Cited in: Sci Rep. 2015 Oct 30;5:15946. [Abstract]
VX-809 reverses the heat-induced effects in cells including reduction in CFTR, upregulation of COX-2 and increases in PGE2.
-
PNAS Nexus
VX-445 (elexacaftor) inhibits chloride secretion across human bronchial epithelial cells by directly blocking KCa3.1 channels. [Abstract]2025 Jul 4;4(7):pgaf211. PMID: 40688096 -
J Physiol Sci
Characterization of Δ(G970-T1122)-CFTR, the most frequent CFTR mutant identified in Japanese cystic fibrosis patients. [Abstract]2019 Jan;69(1):103-112. PMID: 29951967
Lumacaftor purchased from MedChemExpress. Usage Cited in: J Physiol Sci. 2019 Jan;69(1):103-112. [Abstract]
Effect of VX-809 on maturation of Δ(G970-T1122)-CFTR protein. Immunoblots for WT-, ΔF508-, and Δ(G970-T1122)-CFTR proteins expressed in CHO cells in the presence of 0, 3, or 10 μM VX-809 at a 37°C for 24 h or b 27°C for 48 h.
-
Mol Biol Cell
2022 Nov 1;33(13):ar120. PMID: 36074076 -
Virology
Structure-based virtual screening of ROCK1 inhibitors for the discovery of Enterovirus-A71 antivirals. [Abstract]2023 Aug:585:205-214. PMID: 37384967 -
-
-
-
Solvent & Solubility
DMSO : 25 mg/mL (55.26 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 3 mg/mL (6.63 mM); Clear solution
This protocol yields a clear solution of ≥ 3 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (30.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
Screening is carried out using a Beckman Coulter Biomek FX platform. In one set of assays, R1070W-F508-CFTR-HRP (R1070W-HRP)-expressing CFBE41o- cells are incubated with 100 µL medium containing 25 µM test compounds and 0.5 μg/mL Doxycycline for 24 hours at 37°C. In a second set of assays, F508-CFTR-HRP (F508-HRP)-expressing CFBE41o- cells are incubated with 100 µL medium containing 25 µM test compounds, 2 µM Lumacaftor, and 0.5 μg/mL doxycycline for 24 hours at 37°C. All compound plates contain negative controls (DMSO) and positive controls (2 µM Lumacaftor). In both assays, the cells are washed four times with PBS, and HRP activity is assayed by the addition of 50 µL/well of HRP substrate. After shaking for 5 minutes, chemiluminescence is measured using a Tecan Infinite M1000 plate reader equipped with an automated stacker (integration time, 100 milliseconds)[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
.A549 cells expressing F508-CFTR YFP are grown at 37°C/5% CO2 for 18-24 hours after plating. The cells are then incubated with 100 μL of medium containing test compounds for 18-24 hours. At the time of the assay, cells are washed with PBS and then incubated for 10 minutes with PBS containing forskolin (20 μM) and genistein (50 μM). Each well is assayed individually for I- influx by recording fluorescence continuously (200 milliseconds per point) for 2 seconds (baseline) and then for 12 seconds after rapid addition of 165 μL PBS in which 137 mM Cl- is replaced by I-. The initial I- influx rate is computed by fitting the final 11.5 seconds of the data to an exponential for extrapolation of initial slope, which is normalized for background-subtracted initial fluorescence. All compound plates contain negative controls (DMSO vehicle) and positive controls (5 µM Lumacaftor). Fluorescence is measured using a Tecan Infinite M1000 plate reader equipped with a dual syringe pump (excitation/emission 500/535 nm)[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Rats[1]
Male rats (n=3 per dose group) are orally administered Lumacaftor in a vehicle consisting of 0.5% Tween80/0.5% methylcellulose/water at a dose volume of 5 mL/kg. The concentration of Lumacaftor in plasma samples is determined with a liquid chromatography/tandem MS method. Pharmacokinetic parameters are calculated byusing WinNonlin Professional Edition software.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (285 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Van Goor F, et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci U S A. 2011 Nov 15;108(46):18843-8. [Content Brief]
[2]. Phuan PW, et al. Synergy-based small-molecule screen using a human lung epithelial cell line yields ΔF508-CFTR correctors that augment VX-809 maximal efficacy. Mol Pharmacol. 2014 Jul;86(1):42-51. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.2104 mL | 11.0519 mL | 22.1038 mL | 55.2596 mL |
| 5 mM | 0.4421 mL | 2.2104 mL | 4.4208 mL | 11.0519 mL | |
| 10 mM | 0.2210 mL | 1.1052 mL | 2.2104 mL | 5.5260 mL | |
| 15 mM | 0.1474 mL | 0.7368 mL | 1.4736 mL | 3.6840 mL | |
| 20 mM | 0.1105 mL | 0.5526 mL | 1.1052 mL | 2.7630 mL | |
| 25 mM | 0.0884 mL | 0.4421 mL | 0.8842 mL | 2.2104 mL | |
| 30 mM | 0.0737 mL | 0.3684 mL | 0.7368 mL | 1.8420 mL | |
| 40 mM | 0.0553 mL | 0.2763 mL | 0.5526 mL | 1.3815 mL | |
| 50 mM | 0.0442 mL | 0.2210 mL | 0.4421 mL | 1.1052 mL |
Powered by Bioz